Altimmune Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
12. Net Loss Per Share
- Net Loss Per Share
Because the Company has reported net loss attributable to common stockholders for the years ended December 31, 2024 and 2023, basic and diluted net loss per share attributable to common stockholders in each year are the same.
Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average numbers of shares of common stock outstanding for the period.
Diluted net loss per share is calculated by adjusting weighted-average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period. As such, all unvested RSUs, common stock warrants, and stock options have been excluded from the computation of diluted weighted-average shares outstanding because such securities would have an anti-dilutive impact for all periods presented.
Potential common shares issuable upon conversion, vesting or exercise of unvested RSUs, common stock warrants, and stock options that are excluded from the computation of diluted weighted-average shares outstanding, as they are anti-dilutive, are as follows:
| | | | | |
|---|---|---|---|---|
| · · Year Ended December 31, | ||||
| | | 2024 | | 2023 |
| Common stock warrants | — | 50,000 | ||
| Common stock options | 6,666,131 | 5,105,169 | ||
| Restricted stock units | | 858,290 | | 604,167 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.